Skip to main content
. Author manuscript; available in PMC: 2015 Nov 30.
Published in final edited form as: Stat Med. 2014 Jul 20;33(27):4715–4733. doi: 10.1002/sim.6269

Table 1.

Baseline characteristics of patients and summary of PFS in each treatment group

Pemetrexed/Cisplatin
n=208 (%)
Cisplatin
n=217 (%)
Covariates Race: White 189 (91%) 202 (93%)
Gender: Male 169 (81%) 177 (82%)
Age: ≥ 65 80 (38%) 83 (38%)
Karnofsky: High (90-100) 112 (54%) 124 (57%)
Stage: I/II 48 (23%) 46 (21%)
Vitamin Supplement: Full 156 (75%) 158 (73%)

PFS
(in months)
Minimum 0.4 0
Median 6.1 3.6
Maximum 27.1 21.8
Mean 7.0 4.8